Belite Bio is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting eye diseases. It focuses on retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. The lead product candidate is LBS-008, or Tinlareban, an oral once-a-day treatment.